Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study monitors BRCA carriers for early cancer signs

NCT ID NCT03296826

Knowledge-focused Sponsor: Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 600 Japanese women who carry BRCA1 or BRCA2 gene changes to see how often they develop ovarian, fallopian tube, or peritoneal cancers. Participants are monitored over time, and researchers also check tissue samples from those who choose preventive surgery. The goal is to better understand cancer risks in this specific group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 600 people

The number the study aims to enrol. It can still change while the study runs.

Started

Nov 2017

Expected to finish

Mar 2032

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

BRCA1 and/or BRCA2 variant carriers

Ages

20 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Women carrying BRCA1/2 variants (those with either BRCA1 or BRCA2 variants, or those carrying both variants) and women carrying a variant of uncertain significance (VUS). 2. Women who have received sufficient genetic counseling at any medical institution, prior to enrollment to the study. 3. Women who provide consent should be 20 years of age or older. 4. Women who provide written consent. Exclusion Criteria: 1. Women without ovarian or fallopian tube cancer at the time of informed consent. 2. Women previously diagnosed with ovarian, fallopian tube, or peritoneal cancer, and not excluding those with a personal history of breast cancer development. 3. Other individuals considered inappropriate for involvement in this study by the investigator.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRCA1 and/or BRCA2 variant carriers are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

fallopian tube neoplasm ovarian cancer fallopian tube carcinoma prevention target ovarian carcinoma prevention target peritoneal carcinoma prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRCA1 and/or BRCA2 variant carriers Fallopian tube carcinoma Ovarian carcinoma Peritoneal carcinoma

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Okayama University

    RECRUITING

    Okayama, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.